Guwahati Mail

DelveInsight Business Research LLP

DelveInsight’s “EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the EGFR Inhibitors-Induced Skin Disorders, historical and forecasted epidemiology as well as the EGFR Inhibitors-Induced Skin Disorders market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

EGFR-Induced Skin Disorders Market Key Highlights 

• Key Companies working in the EGFR-Induced Skin Disorders  Market market include AstraZeneca, Novartis, Pfizer, and many others.

• Key Therapies included in the EGFR-Induced Skin Disorders  Market market includeTriamcinolone, Diprosone, and many others 

EGFR-Induced Skin Disorders Market Overview

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.

The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer.

Epidermal growth factor and its receptor were discovered by Stanley Cohen of Vanderbilt University. Cohen shared the 1986 Nobel Prize in Medicine with Rita Levi-Montalcini for their discovery of growth factors.

EGFR-Induced Skin Disorders Market Epidemiology Insights

• Up to 90% of cancer patients treated with EGFR inhibitors have skin adverse reactions. Of these, 76% of patients reported that they interrupted the EGFR inhibitor therapy, 32% of patients completely discontinued the EGFR inhibitor therapy, and 60% of patients reduced the dose of the EGFR inhibitor

Click here to learn more about the EGFR-Induced Skin Disorders Market Landscape

The Report Covers the EGFR-Induced Skin Disorders  Market Epidemiology Segmented by:

• EGFR-Induced Skin Disorders prevalent cases 

• EGFR-Induced Skin Disorders incident cases 

• EGFR-Induced Skin Disorders treatment cases 

• EGFR-Induced Skin Disorders diagnosed cases 

EGFR-Induced Skin Disorders Market Outlook 

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.

The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer.

Epidermal growth factor and its receptor were discovered by Stanley Cohen of Vanderbilt University. Cohen shared the 1986 Nobel Prize in Medicine with Rita Levi-Montalcini for their discovery of growth factors.

 Key Companies Working in the EGFR-Induced Skin Disorders Market 

• AstraZeneca

• Novartis 

And many others 

 EGFR-Induced Skin Disorders  Market Therapies Covered and Analyzed in the Report

• Triamcinolone

• Diprosone

And many others 

Learn more about the Key Companies and Emerging Therapies in the EGFR-Induced Skin Disorders  Market

Table of Contents 

1.  Key Insights 

2.  EGFR-Induced Skin Disorders  Market Introduction 

3.  Executive Summary of EGFR-Induced Skin Disorders  Market         

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  EGFR-Induced Skin Disorders  Market Emerging Therapies

7.  EGFR-Induced Skin Disorders  Market Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Market Drivers 

10.  Market Barriers 

11.  Appendix

12.  Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Learn about the detailed offerings of the report @ EGFR-Induced Skin Disorders Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services